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ABSTRACT
Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast
cancer with limited treatment options. Epidermal growth factor receptor I
(EGFR) has emerged as a promising target in TNBC. Limited success of the
EGFR kinase inhibiting small molecules in clinical trials may be attributed in
part to inaccuracy in identifying EGFR signatures in patient tumors. In light
of the absence of a simple correlation between EGFR expression and its
degree of activation, a simple and reliable tool that can quantify EGFR kinase
activity in tumor samples may be of therapeutic value in predicting patient-
specific EGFR targeted therapies. This study reports the development of an
assay that can quantitatively profile EGFR kinase activities and inhibitor
sensitivities in TNBC cell lysates by using peptide reporters covalently
tethered to magnetic beads in a controlled orientation. The use of magnetic
beads provides rapid sample handling and easy product isolation. The po-
tential of this approach was demonstrated by screening a set of five clinically
relevant EGFR tyrosine kinase inhibitors. Formatted for microwell plates, this
magnetic bead-based kinase assay may be used as a complementary ap-
proach for direct high-throughput screening of small molecule inhibitors.
INTRODUCTION
P
rotein tyrosine kinases (PTKs) regulate important cellular
processes in normal cells as well as in several diseases, in-
cluding cancer.1,2 Realizing the importance of kinases as
therapeutic drug targets, several methods have been un-
dertaken to assess protein activity in cancer cells. Conventional as-
says of kinase activity involved detecting incorporation of terminal
phosphate from P32-labeled ATP. Recent years have witnessed the
development of several high-throughput kinase assays, including
arrays of antibodies, to capture PTKs followed by detection of
phosphotyrosine content with secondary antibodies.3 These methods,
however, require antibodies for selective recognition of phosphory-
lated residues. Arrays of immobilized proteins or peptides have also
been developed to profile kinase activity directly. In its simplest form,
a kinase assay monitors the phosphorylation of a substrate in the
presence of kinase and ATP. Experimentally derived consensus
motifs and random peptide libraries have been screened to identify
exogenous substrate sequences with high specificity and rates of
reactivity.4,5 Unlike antibody arrays, these peptide microarrays offer
multiplexed detection of kinase activity with spatial addressing,
thereby facilitating the quantification of multiple kinase activities
using a single anti-phosphotyrosine antibody. Diverse approaches
have been developed to immobilize protein or peptide substrates onto
solid surfaces, including peptide synthesis in situ,6,7 noncovalent
attachment via streptavidin–biotin interaction, covalent attachment
via chemical ligation, N-hydroxysuccinimide (NHS)–amine reaction,
Diel–Alder reaction and Michael addition,8–12 attachment of self-
assembled monolayers of alkanethiols on gold surfaces,9 as well as
copolymerization into polyacrylamide gels.13,14 Thus, while numer-
ous specific surface-attachment strategies have been devised, none
has yet been widely accepted due to inherent challenges in these
approaches, including reduced protein activity due to dehydration or
denaturation, reduced surface density due to steric hindrance, and
difficulty in adaptation to high-throughput screening.
Triple-negative breast cancer (TNBC), lacking estrogen receptor,
progesterone receptor and human epidermal growth factor receptor
2 (HER2), poses a serious clinical challenge because of poor prog-
nosis,15–17 extreme aggressiveness, and metastasis.16,17 Limited
treatment options exist for TNBC and recurrence is common. Hence,
several initiatives have been undertaken to identify clinically
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relevant molecular targets in TNBC. Epidermal growth factor receptor
(EGFR), which is expressed in around 60%of TNBCs, has emerged as a
promising clinical target.18–20 Even though the use of EGFR tyrosine
kinase inhibitors (e.g., gefitinib and erlotinib) has shown promising
results in vitro with basal-like breast cancer cell lines,21,22 clinical
trials of these drugs in breast cancer have not been as successful.23,24
This lack of clinical response can be partially attributed to inefficiency
in identifying tumors with increased EGFR activity.18,23,24 A sensitive
and reliable method to detect EGFR abnormalities in breast cancer
cells would likely identify a cohort of patients who would benefit from
EGFR targeted therapies. The absence of a simple relationship between
receptor expression and its degree of activation probably led to the
failure of the clinical trials, which explored the response to anti-EGFR
drugs based only on protein expression.18 Under these circumstances,
profiling EGFR kinase activity signature in breast cancer samples
would not only provide a more accurate report of the disease state, but
also may be more successful in screening inhibitors and monitoring
treatment progression of individual patients. Hence, there is an urgent
need of a simple, robust yet cost-effective platform for high-
throughput screening of small molecule drug candidates.
Major challenges in developing cell-based PTK assays involve
sensitive and specific detection of the activity of one PTK in the
background of multiple tyrosine kinases present in cellular extracts
and obtaining accurate measurements from small biopsy samples.
Solid-phase kinase assays, where either the kinase or the substrate is
tethered to solid surfaces, have several advantages over solution/
homogeneous phase kinase assays, including easing purification and
facilitating scale-down of the assay. In this study, the peptide re-
porters were covalently tethered to magnetic beads in a controlled
orientation via a COOH-terminal cysteine residue on peptide sub-
strates byMichael addition chemistry. The immobilized substrate was
then incubated either with recombinant EGFR or cellular extracts of
TNBC cells with or without small molecule EGFR tyrosine kinase
inhibitors (EGFR-TKIs). Substrate phosphorylation, measured via
chemifluorescence, was sensitive and provided selective quantifica-
tion of kinase activity in cancer cells. This assay also allowed for
direct screening of small molecule EGFR kinase inhibitors.
EXPERIMENTAL
Preparation and Purification of Peptide
Amino acids, CLEAR-Amide resin, and 2-(6-chloro-1-H-
benzotriazole-1-yl)-1,1,3,3-tetramethylaminium haxafluorophosphate
(HCTU) were obtained from Peptides International. Piperidine, N-
methylmorpholine, trifluoroacetic acid (TFA), 1,2-ethanedithiol
(EDT), and triisopropylsilane (TIS) were obtained from Sigma-
Aldrich. All reagents were used as received without any purification.
The peptides KKKAEEEEYFELVAC, SPAFDNLYYWDQDPPERC,
KKAFDNPDYWNHSLPPRC, KKKSNFANFSAYPSEEDMC, RRLIEDN
EYTARGC, and ADEYLIPQQC were synthesized on an automated
synthesizer, Prelude (Protein Technologies, Inc.), using a solid-
phase method based on Fmoc-chemistry. Cleavage of the crude
peptide was performed with the mixture of TFA/ddH2O/EDT/TIS
(94:2.5:2.5:1 v/v) at room temperature (RT). The crude peptide was
then precipitated and washed with cold diethyl ether three times. The
crude peptides were tested using ABI 4700 MALDI TOF/TOF mass
spectrometry (Applied Biosystems) to confirm the correct molecular
masses and Agilent 1200 Series LC/MS system for purity. Purification
was done through a preparative C18 column in the Agilent 1200 LC/
MS system if necessary.
Cell Culture and Lysate Production
Human breast cancer (MDA-MB-468 and MDA-MB-231) cells
were maintained in RPMI-1640 supplemented with 10% fetal bovine
serum (FBS) and glutamine, whereas MCF-7 cells were grown in
DMEM supplemented with FBS and glutamine (supplemented
DMEM). To maintain full length HER2 cDNA transfected MCF-7
(MCF-7/HER2) cells, 10 mg/mL insulin and 0.4 mg/mL G418 were
added in supplemented DMEM. During the culture, the media were
changed every other day. The cells were passaged every 5–6 days
using Trypsin-EDTA (0.25% trypsin, 1mM EDTA). To lyse the cells,
the cells were washed 2· with cold phosphate-buffered saline (PBS),
and then 1mL of cold lysis buffer (50mM HEPES, 150mM NaCl,
1.5mM MgCl2, 1mM EDTA, 100mM NaF, 10mM sodium pyro-
phosphate, 1% Triton X-100, and 10% glycerol) containing 1·
protease inhibitor cocktail, 1mM phenylmethylsulfonyl fluoride, and
1mM activated sodium orthovanadate was added to each cell flask.
The cells were incubated on ice for 15min with occasional swirling,
then removed from the plate with a cell scraper, and transferred to a
microcentrifuge tube. The cell lysate was then clarified by centri-
fuging at 14,000 g at 4C for 15min. Total protein concentration was
determined using a BCA protein assay kit (Pierce), and the lysates
were stored at - 80C until further use.
Kinase Inhibitors
Gefitinib and erlotinib were procured from LC Labs, CL-387,785
from EMD Chemicals and BIBW-2992 and CI-1033 from Chemietek.
Substrate Immobilization on Bead Surface
COOH terminated magnetic beads were procured from Bioclone.
As illustrated in Figure 1A, a simple attachment strategy was utilized
to covalently immobilize peptide substrates on to the beads. 300 mL of
magnetic beadswere thoroughlywashed. Amagnetic stand (DynaMag-2
magnet; Invitrogen) was used to collect the beads. Following incu-
bation with 50mg/mL of 1-ethyl-3-[3-dimethylaminopropyl] car-
bodiimide hydrochloride (EDC) and 50mg/mL of NHS for 30min at
RT with gentle shaking, the beads were washed 3· with 100mM
MES buffer (pH: 5.0) and resuspended in 10mM cystamine dihy-
drochloride solution in the same buffer. The reaction was carried
out for 2 h at RT. After the completion of the coupling reaction,
the beads were collected, washed, and incubated with 50mM tris
(2-carboxyethyl)phosphine (TCEP) for 30min at RT. The activated
beads were washed again and functionalized with Sartomer SR 415
(Exton) in 100mM NaHCO3 (pH 8.4) for 30min. After washing the
beads 3· in water, the remaining unreacted thiol groups were
blocked with 2M sodium acrylate in 100mM Na2CO3 for 30min.
Finally, beads were incubated with peptides diluted in a 100mM
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NaHCO3 solution for 3 h at RT. Following the conjugation reaction,
the beads were washed in TBST (10mM Tris-HCl, 100mM NaCl, and
0.15% Tween-20), and then in water before storing at 4C.
Evaluation of Loading Capacity of the Beads
100 mL of magnetic beads was conjugated to 100 mL of 550 mmoles/
L peptide substrates for 3 h as described earlier. Following the reac-
tion, magnetic beads were separated from the mixture using the
magnetic stand and the clear supernatant was collected. The con-
centration of the unbound substrate in the supernatant was evaluated
using the BCA protein assay kit and the difference in concentration of
the substrates before and after conjugation reaction was then utilized
to calculate the loading capacity of the beads for the substrates.
Array-Based Kinase Assay
To carry out the kinase assay, initially the beads were added to
each well of a 96-well plate and blocked with 10% bovine serum
albumin (BSA) in the EGFR kinase buffer
(20mM HEPES pH: 7.2, 10mM MnCl2,
1mM DTT, 15mM MgCl2, and 40 mg/mL
BSA) for 30min at RT. The substrate was
then incubated with the reaction mixture
consisting of recombinant EGFR or cell
lysates (at indicated concentrations), 6 mL
of 1mM ATP, 20 mL of 3· EGFR kinase
assay buffer, 6 mL of 50% glycerol and
water (total volume of 60 mL) at RT. Typi-
cally 5 mL of substrate-conjugated beads
was used for each reaction. EGFR-TKIs at
varying concentrations were incubated
with cell lysates for 30min at RT before
performing the kinase assay.
Detection and Quantification
of Phosphorylated Substrates
After the reaction, the beads were wa-
shed with TBST and blocked in TBST
containing 1% BSA for 1 h at RT. This was
followed by incubation of the beads with
horseradish peroxidase (HRP)-conjugated
4G10 anti-phosphotyrosine (Millipore)
antibody for 1 h at RT. The beads were then
washed 3· with TBST and resuspended in
50mM sodium phosphate (pH: 7.5) buf-
fer. For chemifluorescent detection, 50mL
of freshly prepared 50mM Amplex red
and 1mM H2O2 (in the sodium phos-
phate buffer) was added to each well.
The fluorescent intensity was detected
using a Quad-4-monochromator micro-
plate reader (Tecan Safire 2) with an
excitation wavelength of 532 nm and an
emission wavelength of 590 nm. Dose–
response curve fits were generated (3 parameter fit in GraphPad
Prism) by plotting fluorescence units/s against log concentration
of inhibitors.
Statistical Analysis for Assay Evaluation
To statistically analyze the dynamic range and reproducibility
of the assay, a fluorescent signal obtained upon incubation with
the MDA-MB-468 cell lysate was considered the positive control,
whereas that obtained from the EGFR-immunodepleted MDA-MB-
468 supernatant was regarded as the negative control. The signal/
background (S/B) ratio was calculated as lpos/lneg, whereas the
signal/noise (S/N) ratio was evaluated as (lpos - lneg)/rneg . lpos and
rpos are the mean and standard deviation of positive controls,
whereas lneg and rneg are mean and standard deviation of negative
controls, respectively. The Z-factor, a dimensionless number which
represents both the dynamic range and variability across multiple
samples, was calculated from 1 - [3 · (rpos + rneg)/jlpos - lnegj].25
Fig. 1. (A) Peptide reporters were covalently attached to the magnetic beads in a controlled
orientation. (B) Immobilized peptide was then incubated with different reaction mixtures.
Quantitative profiling of phosphorylated status of EGFR and sensitivities of EGFR to inhibitors
using a magnetic bead assay. Following the reaction, the phosphorylation of the substrates
was detected by chemifluorescence. EGFR, epidermal growth factor receptor.
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The Z-factor ranges from negative values to 1, but values greater
than 0.5 are considered to be adequate.
Cell Viability Assay
MDA-MB-468 cells were seeded at a density of 5·103 cells/well in
96-well plates. After 24h, erlotinib, gefitinib, CL-387,785, CI-1033, and
BIBW-2992 at varying concentrations were added and the cells were
incubated further for 48h. The cellswere thenwashedwith PBS and cell
viability was measured using a XTT assay kit (Sigma). A dose–response
curve fit was generated (3 parameter fit in GraphPad Prism) by plotting
inhibition of cell growth against log concentration of inhibitors.
RESULTS AND DISCUSSION
To develop a simple yet robust and reproducible assay formonitoring
EGFR activity and inhibitor sensitivities, peptide substrates were cova-
lently immobilized onto the magnetic beads. After kinase reactions, the
beadswerewashed and phosphorylation of the peptides was detected by
chemifluorescence using an HRP-conjugated primary antibody against
phosphorylated tyrosine (Fig. 1B). The fluorescence intensity measured
is directly proportional to substrate phosphorylation, which in turn is
proportional to EGFR kinase activity in cancer cells.
Development of Kinase Assay with Substrate-Immobilized
Magnetic Beads
Six different peptides specific for the EGFR kinase (Table 1) were
designed based on either the optimal EGFR substrate sequence or
sequences that had been previously shown to be efficiently phosphor-
ylated by EGFR in vitro.26–30 To increase substrate accessibility, and
hence peptide density on the bead surface, substrates were immobilized
on the beads via a cross linker, Sartomer SR415. Earlier studies in our
group directed at evaluating the effect of different cross linkers on
substrate accessibility showed that SR415 markedly increased peptide
density as compared to bisacrylamide and other branched PEG linkers.11
Cystamine was conjugated to COOH-terminated magnetic beads utiliz-
ing EDC/NHS chemistry. Reduction of disulfide bonds by TCEP gener-
ated free thiol groups, which were then conjugated to the cross linker
SR415. Substrates were covalently attached to the cross linker by
Michael addition of the sulfhydryl group at the COOH-terminal cysteine.
As described in Materials and Methods, the concentration of unbound
peptide was calculated using a BCA protein assay kit, and the difference
in peptide concentration before and after conjugation reaction was
utilized to estimate the loading capacity of the beads. The loading ca-
pacity was estimated to be 15·10-17 moles of peptide substrate/bead.
To test the peptide substrate accessibility to EGFR and detection of
antibodies as well as the sensitivity of detecting substrate phos-
phorylation, substrate-immobilized beads were incubated with seri-
ally diluted purified recombinant EGFR for 1 h in the presence of ATP
and substrate phosphorylation was evaluated via chemifluorescence.
Table 1. Sequences of Different EGFR
Kinase-Specific Peptides
Peptide number Sequence Reference
1 KKKAEEEEYFELVAC 26–28
2 SPAFDNLYYWDQDPPERC 26,27
3 KKAFDNPDYWNHSLPPRC 26,27
4 KKKSNFANFSAYPSEEDMC 28,29
5 RRLIEDNEYTARGC 26,27
6 ADEYLIPQQC 26,27
Fig. 2. (A) Selection of peptide substrate. Peptides 1–6 (Table 1)
were immobilized onto the magnetic beads and incubated for 1 h
with 0–400ng/mL of purified recombinant EGFR. Comparison of
substrate phosphorylation following incubation of beads with or
without peptide substrates with varying concentration of EGFR.
Each data point represents the mean of three independent exper-
iments in which each experiment contained three replicates. The
error bars represent SEM (n= 3). (B) Specificity of phosphorylation
of immobilized peptides 1 and 4 by EGFR. Substrate-conjugated
beads were incubated for 1 h with 100mg of MDA-MB-468, EGFR-
immunodepleted MDA-MB-468 supernatant, K562 lysate, MCF-7,
MCF-7/Her2, and no lysate control and substrate phosphorylation
was detected by chemifluorescence. Each data point represents the
mean of three independent experiments in which each experiment
contained three replicates. The error bars represent SEM (n= 3).
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As a control, EGFR was added to beads lacking immobilized peptides.
The significant difference in fluorescent intensity obtained from
beads with and without substrates (Fig. 2A) demonstrated the po-
tential of this magnetic bead-based assay to detect peptide phos-
phorylation with high sensitivity. Of the peptide substrates tested,
significantly higher signals were obtained for peptide 1 and peptide 4
than the other peptides (P < 0.05 at 100 and 400 ng/mL EGFR), in-
dicating peptides 1 and 4 were more efficiently phosphorylated by
EGFR in vitro.
Major challenges in developing a kinase assay include identifying
a highly specific substrate and sensitively detecting phosphorylation
of this substrate because cancer cell lysates contain multiple tyrosine
kinases, which can potentially contribute toward the phosphoryla-
tion of the substrate. So, to evaluate the specificity and detection
sensitivity of EGFR phosphorylation of peptides 1 and 4, the sub-
strates were incubated for 1 h with 100 mg of cellular extracts of the
TNBC cell line, MDA-MB-468 (TNBC with high EGFR expression),
MCF-7 (luminal breast cancer with a very low EGFR expression),31,32
MCF-7/HER2 (MCF-7 cells expressing HER2),33 K562 (human
chronic myeloid leukemia cell line lacking EGFR expression),30,34
supernatant of EGFR-immunodepleted MDA-MB-468, and a no-
lysate control. As demonstrated in Figure 2B, a high signal was ob-
tained for MDA-MB-468 cells in case of both the peptide reporters
(13 and 20 units/s for peptide 1 and 4, respectively), as compared to
K562, MCF7, and MCF7/HER2 cells (4, 3, and 2 units/s and 3, 4, and
3 units/s for peptide 1 and 4, respectively). Also, very little phos-
phorylation of immobilized substrates was observed for the EGFR-
immunodepleted MDA-MB-468 supernatant and no lysate control
(2 and 2 units/s and 1 and 3 units/s for peptide 1 and 4, respectively),
indicating that kinases other than EGFR contributed very little to-
ward the phosphorylation of either peptide reporters under these
reaction conditions (Fig. 2B). Several parameters were calculated to
identify the optimal substrate for further development of the kinase
assay. Using the signal obtained upon incubating MDA-MB-468 cell
lysates as the positive control and that obtained from the EGFR-
immunodepleted MDA-MB-468 supernatant as the negative control,
the Z-factor was calculated to be 0.7 for peptide 1 and 0.75 for
peptide 4. This suggested that the dynamic range as well as variability
across multiple samples for both the peptide reporters is comparable.
However, since the S/B and S/N ratios for peptide 1 were lower than
those of peptide 4 (6 vs. 18.2 S/B and 64 vs. 111.2 S/N), peptide 4 was
chosen as the substrate for further development.
Substrate Optimization
Initial studies were directed toward optimizing the kinase reaction
conditions. To assess the dynamic range of the bead-based assay,
peptide 4-conjugated magnetic beads were incubated with serially
diluted MDA-MB-468 cell lysates for 1 h. As illustrated in Figure 3A,
increasing total lysate protein from 0 to 75 mg enhanced substrate
phosphorylation. However, further increases in cell lysate amount
did not increase substrate phosphorylation significantly. As com-
pared to the no lysate control, a statistically significant difference in
substrate phosphorylation was observed (P< 0.05) when the protein
array was incubated with 10 mg cell lysates, which corresponded to
approximately 500 cancer cells. Using the signal obtained upon in-
cubation with no lysate as a negative control, Z-factors were
- 0.03, 0.25, 0.7, and 0.8, and S/N ratios were 8.1, 12.1, 27.8, and
33.01, for 10, 25, 50, and 75 mg MDA-MB-468 cell lysate. Since
Fig. 3. Optimization of total protein in MDA-MB-468 cell lysate and
reaction time. (A) 0–100 mg cell lysate was incubated with peptide
4 for 1 h. Extent of substrate phosphorylation was quantified by
chemifluorescence and is presented as units/s. Each data point
represents the mean of three replicates and the error bars repre-
sent SEM. (B) Extent of substrate phosphorylation was quantified
by incubating peptide 4 with 50 mg of MDA-MB-468 cell lysate.
Each data point represents the mean of three independent ex-
periments in which each experiment contained three replicates of
each sample, and the error bars represent SEM (n = 3). (C) Extent
of substrate phosphorylation as a function of ATP concentration.
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Z-factor values and S/N ratios obtained with 50 mg cell lysate were
higher than those obtained for 10 and 25 mg and were comparable to
those obtained with 75 mg of cell lysate, the phosphorylation of the
substrate at different time points (Fig. 3B) for up to 60min was then
monitored using 50 mg of cell lysate per reaction. As expected, sub-
strate phosphorylation increased with increased reaction time.
However, beyond 30min, phosphorylation signal saturated, high-
lighting the reduction in reaction rate as the substrate is depleted.
Z-factors were 0.4, 0.7, and 0.7, and S/N ratios were 32, 52, and 52, for
incubation time of 15, 30, and 60min. Hence, all subsequent experi-
ments were performed with 30min incubation in the cell lysate. The
concentration of ATP was varied from 0–150mM. In the absence of
ATP, little phosphorylation signal was detected. Increasing the ATP
concentration from 0 to 50mM resulted in an increased phosphoryla-
tion signal (Fig. 3C). Above 50mM, further increases in the ATP con-
centration had no effect on the substrate phosphorylation signal. The
ATP concentration used for all subsequent experiments was 100mM.
Inhibitor Screening in Cell Lysates
After confirming the ability of the magnetic bead-based assay to
quantitatively profile EGFR activity status in cellular extracts, experi-
ments were designed to investigate its potential utility in screening
clinically relevant kinase inhibitors. For this purpose, peptide 4-
conjugated magnetic beads were incubated with MDA-MB-468 cell
lysates in the presence of five different ATP competitive inhibitors at
concentrations varying from 0.1 to 10mM. The inhibitors tested include
the first generation inhibitors erlotinib and gefitinib (EGFR specific), as
well as the second generation irreversible inhibitors CL-387,785 (EGFR
specific), CI-1033 (pan-EGFR), and BIBW-2992 (EGFR-ErbB2 dual
inhibitor). Figure 4A demonstrates the dose-dependent reduction of
substrate phosphorylation by each inhibitor. First generation inhibitors,
erlotinib and gefitinib, had moderate effects on substrate phosphory-
lation as compared to the second generation inhibitors. Table 2 com-
pares the IC50 of different inhibitors. Higher potency of second
generation inhibitors is probably due to the ability of these inhibitors to
covalently bind to the cysteine residue in the ATP binding pocket of the
EGFR kinase domain via a Michael addition reaction. The covalent
attachments ensure a higher occupancy of the ATP binding site and
Fig. 4. (A) Comparison of the effects different EGFR inhibitors on
the phosphorylation of immobilized peptide 4 upon incubation
with 50 mg of MDA-MB-468 cell lysates for 30min. (B) Compar-
ison of the effect of different EGFR inhibitors on the viability of
MDA-MB-468 cells. (C) Comparison of the effect of erlotinib and
CL-387,785 on substrate phosphorylation when incubated with
MDA-MB-468 and MDA-MB-231 cells. Each data point represents
the mean of three independent experiments in which each ex-
periment contained three replicates. The error bars represent
SEM (n = 3).
Table 2. Comparison of IC50 Values of Different EGFR Kinase
Inhibitors Between Kinase Assay and Cell Proliferation Assay
Bead-based assay Cell proliferation assay
Erlotinib 7.2– 2.1 8.5– 3.1
Gefitinib 8 – 3.1 8.1– 2
CL-387,785 0.7– 0.3 2.2– 0.6
BIBW-2992 1.0– 0.9 2.2– 1.0
CI-1033 1.4– 0.8 2.5– 0.8
Each data point represents the mean– SD (n= 3), expressed in mM.
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thus enable these TKIs to inhibit the activation of EGFR. Further ex-
periments were performed to examine the effect of these inhibitors on
viability of MDA-MB-468 cells. As shown in Figure 4B, inhibitors in-
duced a dose-dependent growth inhibition of the cells, with second
generation inhibitors being more efficient than first generation inhib-
itors. As illustrated in Table 2, IC50 values obtained for the cell viability
assaywere comparable to that of the bead-based assay, highlighting the
ability of the magnetic bead assay to act as a complimentary approach
for direct screening of small molecule inhibitors.
As a further demonstration of the assay as a tool for screening
inhibitors, substrate-conjugated beads were incubated with cellular
extracts of MDA-MB-231 in the presence of erlotinib and CL-
387,785. Figure 4C compares the effects of these compounds on
MDA-MB-468 and MDA-MB-231 cells. Both of these are TNBC cell
lines; however, MDA-MB-231 cells are highly invasive, while MDA-
MB-468 cells are not.35 Both the cell lines showed increased sensi-
tivity toward CL-387,785 [IC50 values (mM) of 0.7 – 0.3 and 0.5– 0.2
(CL-387,785) vs. 5.6 – 2.5 and 7.2 – 1.5 (erlotinib) for MDA-MB-468
and MDA-MB-231, respectively]. Thus, this study illustrates the
potential of the bead-based assay to screen for inhibitors irrespective
of the aggressive or metastatic characteristic of cancer.
In summary, we report here the development of a sensitive and
robust magnetic bead-based assay to achieve sensitive, selective, and
quantitative measurement of EGFR kinase activity in TNBC cells
using chemifluorescence detection as read out. The study demon-
strated the ability of this assay to monitor EGFR activity and screen
for small molecule compounds to inhibit EGFR activity in TNBC cell
lines and highlighted the translational relevance of the assay. By
incubating substrate tethered beads with lysates prepared from
patient-derived fine-needle aspirations, this assay can be used to
predict the response of an individual patient to kinase inhibitor therapy
based on the decline of kinase activity in the presence of tyrosine
kinase inhibitors. Thus, this method may be helpful in identifying
cohorts of TNBC patients who would benefit from EGFR kinase in-
hibitor therapy and predicting appropriate treatment. Furthermore,
this assay has the potential to be expanded to multiplexed format for
simultaneous quantitative analysis of different kinases, which are
crucial for cancer progression and to accurately predict individualized
kinase inhibitor cocktails and monitor patient response.
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